Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study

NCT00443391 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT00443391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00443391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
October 31, 2008
Enrollment
141 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder